Literature DB >> 18841343

[Guideline-adherent treatment for asthma].

M Sieren1, R Buhl, C Taube.   

Abstract

Asthma is a complex syndrome with numerous clinical phenotypes. An increase in prevalence is detectable worldwide. Efforts to optimize diagnosis and care of patients with asthma have led to the development of international and national guidelines. Besides preventive and non-pharmacological measures such as patient education and physical training, the guidelines particularly recommend standardized drug therapy. In the present article we summarize the recommended pharmacotherapy for patients with bronchial asthma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18841343     DOI: 10.1007/s00108-008-2134-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  31 in total

1.  Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial.

Authors:  Robert S Zeiger; Steven R Bird; Michael S Kaplan; Michael Schatz; David S Pearlman; E John Orav; Carolyn M Hustad; Jonathan M Edelman
Journal:  Am J Med       Date:  2005-06       Impact factor: 4.965

2.  Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.

Authors:  Paul M O'Byrne; Hans Bisgaard; Philippe P Godard; Massimo Pistolesi; Mona Palmqvist; Yuanjue Zhu; Tommy Ekström; Eric D Bateman
Journal:  Am J Respir Crit Care Med       Date:  2004-10-22       Impact factor: 21.405

3.  A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma.

Authors:  D J Evans; D A Taylor; O Zetterstrom; K F Chung; B J O'Connor; P J Barnes
Journal:  N Engl J Med       Date:  1997-11-13       Impact factor: 91.245

4.  The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma.

Authors: 
Journal:  Eur Respir J       Date:  2003-09       Impact factor: 16.671

5.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.

Authors:  Eric D Bateman; Homer A Boushey; Jean Bousquet; William W Busse; Tim J H Clark; Romain A Pauwels; Søren E Pedersen
Journal:  Am J Respir Crit Care Med       Date:  2004-07-15       Impact factor: 21.405

6.  Global strategy for asthma management and prevention: GINA executive summary.

Authors:  E D Bateman; S S Hurd; P J Barnes; J Bousquet; J M Drazen; J M FitzGerald; P Gibson; K Ohta; P O'Byrne; S E Pedersen; E Pizzichini; S D Sullivan; S E Wenzel; H J Zar
Journal:  Eur Respir J       Date:  2008-01       Impact factor: 16.671

7.  Evidence of a role of tumor necrosis factor alpha in refractory asthma.

Authors:  Mike A Berry; Beverley Hargadon; Maria Shelley; Debbie Parker; Dominick E Shaw; Ruth H Green; Peter Bradding; Christopher E Brightling; Andrew J Wardlaw; Ian D Pavord
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

8.  Asthma severity and medical resource utilisation.

Authors:  L Antonicelli; C Bucca; M Neri; F De Benedetto; P Sabbatani; F Bonifazi; H G Eichler; Q Zhang; D D Yin
Journal:  Eur Respir J       Date:  2004-05       Impact factor: 16.671

9.  The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial.

Authors:  J B Morjaria; A J Chauhan; K S Babu; R Polosa; D E Davies; S T Holgate
Journal:  Thorax       Date:  2008-02-01       Impact factor: 9.139

10.  Randomized comparison of strategies for reducing treatment in mild persistent asthma.

Authors:  Stephen P Peters; Nicholas Anthonisen; Mario Castro; Janet T Holbrook; Charles G Irvin; Lewis J Smith; Robert A Wise
Journal:  N Engl J Med       Date:  2007-05-17       Impact factor: 91.245

View more
  1 in total

1.  [Therapy of bronchial asthma according to the guidelines].

Authors:  A Roeser
Journal:  Internist (Berl)       Date:  2009-04       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.